<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04428983</url>
  </required_header>
  <id_info>
    <org_study_id>HELPD V4 20191120</org_study_id>
    <nct_id>NCT04428983</nct_id>
  </id_info>
  <brief_title>The Effect of Hericium Erinaceus Mycelium in Non-motor Symptoms of Parkinson's Disease</brief_title>
  <official_title>The Effect of Hericium Erinaceus Mycelium in Non-motor Symptoms of Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson disease (PD) is considered a multisystemic neurodegenerative disorder, together&#xD;
      with the classic motor disability, and a number of non-motor symptoms (NMS).NMS have a&#xD;
      significant negative relation with patients' quality of life. In general, both medicinal and&#xD;
      nonmedicinal therapies are often advised for PD patients with NMS, but robust evidences for&#xD;
      underpinning the clinical effects are limited. Recently, the search for small preventative&#xD;
      neurotrophic compounds that are responsible for the maintenance, survival of neurons has&#xD;
      attracted much attention. Erinacine A, which is extracted from Hericium erinaceus is the one&#xD;
      showed prominent beneficial effects in the central nervous system. It can increase NGF and&#xD;
      catecholamine content in the locus coeruleus and hippocampus of rats. This markedly increases&#xD;
      neuronal survival in different brain areas and substantially improve behavioral outcomes in&#xD;
      various animal models. In a MPTP-induced Parkinsonism model, treatment with Hericium&#xD;
      erinaceus mycelium reduced the loss of dopaminergic cell, eliminated neuronal apoptosis and&#xD;
      reversed MPTP-associated motor deficits. Thus, this project intends to hold a randomized,&#xD;
      controlled trial to assess the effect of Hericium erinaceus mycelium, which is enriched of&#xD;
      Erinacine A, in NMS of PD. This project will enroll 80 patients with PD. Subjects will be&#xD;
      randomly allocated into study or placebo group. Subjects will take Hericium erinaceus&#xD;
      mycelium for 2 years (one capsule per meal per day) and their treatments for PD will not be&#xD;
      altered.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:&#xD;
&#xD;
        1. PD patients aged 50-79 years diagnosed by neurologist (should exclude vascular&#xD;
           parkinsonism, secondary parkinsonism( including toxin, drug, heavy metal, CO&#xD;
           intoxication), normal pressure hydrocephalus, multiple system atrophy, progressive&#xD;
           supranuclear palsy, cortical basal degeneration, dementia with Lewy Body, hereditary&#xD;
           parkinson's disease with genetic mutation, Huntington's disease, Wilson disease, spinal&#xD;
           cerebellar ataxia with extrapyramidal syndrome, essential tremor, dystonia)&#xD;
&#xD;
        2. PD at Hoehn and Yahr stage 2-2.5&#xD;
&#xD;
        3. without cognitive decline&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        1. with diabetes mellitus (DM)&#xD;
&#xD;
        2. with nephropathy (GFR &lt; 30ml/min)&#xD;
&#xD;
        3. with significant neurological deficits caused by vascular insults&#xD;
&#xD;
      Measurement parameters:&#xD;
&#xD;
        1. At recruitment: blood sugar, AST, ALT, BUN, Crea, Ca, Na, K and peripheral blood cell&#xD;
           (for the expression levels of KATP)&#xD;
&#xD;
        2. every 6 months: motor symptoms: UPDRS, evaluate with UDYSRS if presence with dyskinesia&#xD;
           Non motor symptoms: self-report: PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D,&#xD;
           BPRS&#xD;
&#xD;
        3. every 1 year: CASI, tilting table, AST, ALT, BUN, crea, Na, K, Ca&#xD;
&#xD;
      Protocol:&#xD;
&#xD;
      0 month (initial baseline):&#xD;
&#xD;
        1. blood sugar, AST, ALT, BUN, Crea, Ca, Na, K and peripheral blood cell&#xD;
&#xD;
        2. Tilting table test (autonomic function)&#xD;
&#xD;
        3. CASI cognitive test&#xD;
&#xD;
        4. UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms: self-report:&#xD;
           PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS&#xD;
&#xD;
        5. stool microbiota&#xD;
&#xD;
      6 months: UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms:&#xD;
      self-report: PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS&#xD;
&#xD;
      12 months:&#xD;
&#xD;
        1. UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms: self-report:&#xD;
           PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS&#xD;
&#xD;
        2. CASI cognitive test, tilting table, AST, ALT, BUN, crea, Na, K, Ca&#xD;
&#xD;
      18 months: UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms:&#xD;
      self-report: PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS&#xD;
&#xD;
      24 months:&#xD;
&#xD;
        1. UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms: self-report:&#xD;
           PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS&#xD;
&#xD;
        2. CASI cognitive test, tilting table, AST, ALT, BUN, crea, Na, K, Ca&#xD;
&#xD;
        3. stool microbiota&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">March 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>baseline</measure>
    <time_frame>0 month</time_frame>
    <description>Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1st</measure>
    <time_frame>6 momths</time_frame>
    <description>Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2nd</measure>
    <time_frame>12 months</time_frame>
    <description>Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3rd</measure>
    <time_frame>18 months</time_frame>
    <description>UPDRS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>final</measure>
    <time_frame>24 months</time_frame>
    <description>Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Hericium erinaceus mycelium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hericium erinaceus capsules 1 table tid orally per day for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsules 1 table tid orally per day for 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hericium erinaceus mycelium</intervention_name>
    <description>Hericium erinaceus capsules 3 tables per day for 24 months</description>
    <arm_group_label>Hericium erinaceus mycelium</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  idiopathic PD patients, aged 50-79 years&#xD;
&#xD;
          -  modified Hoehn &amp; Yahr stage 2-2.5&#xD;
&#xD;
          -  Without subjective and objective cognitive decline (objective cognitive decline will&#xD;
             be determined by CASI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With diabetes&#xD;
&#xD;
          -  With end stage renal disease under hemodialysis&#xD;
&#xD;
          -  With significant vascular insults that resulted in significant neurological deficits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Ya Lee</last_name>
    <role>Study Director</role>
    <affiliation>Bioengineering Center, Grape King Bio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li-Ya Lee</last_name>
    <phone>+886-3-4572525</phone>
    <phone_ext>2995</phone_ext>
    <email>ly.lee@grapeking.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan-Ting Sun, MD PhD</last_name>
      <phone>+886-6-2353535</phone>
      <email>ytsun@mail.ncku.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cheng-Kung University Hospital</investigator_affiliation>
    <investigator_full_name>Yuan-Ting Sun</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Parkinson Disease, non-motor symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

